ATEA PHARMACEUTICALS INC (AVIR)
Health Care · biotechnology · NASDAQ
A clinical-stage biopharmaceutical company developing next-generation oral direct-acting antivirals to treat serious viral infections like Hepatitis C and Hepatitis E.
What ATEA PHARMACEUTICALS INC does
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing orally administered, direct-acting antiviral therapies for serious viral diseases. Its pipeline centers on a proprietary nucleos(t)ide platform used to create candidates such as the bemnifosbuvir and ruzasvir combination for hepatitis C and AT-587 for chronic hepatitis E. The company is currently conducting late-stage clinical trials to address significant unmet medical needs in hepatology.
Recent developments
In July 2026, the company reported positive topline Phase 3 results for its HCV regimen (BEM/RZR) in the C-BEYOND trial, achieving statistical non-inferiority to the current standard of care. Additionally, the company initiated a first-in-human Phase 1 trial for AT-587 in July 2026 and expects to file an NDA for its HCV regimen in Q2 2027.
From ATEA PHARMACEUTICALS INC's filing of 2026-08-12.
Themes: antiviral therapeutics, hepatology, HCV treatment, HEV treatment, nucleos(t)ide drug platform, oral drug delivery
Fundamentals
- Price$5.16 as of 2026-10-08 close
- Market cap$413M as of 2026-08-10 (share count; price 2026-10-08)
- 1-year return+66.3% 2025-10-08 close $3.10 → 2026-10-08 close $5.16
- P/En/a negative earnings
- Net margin+34.5% FY2021, SEC XBRL
- ROE-57.5% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta0.69 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How AVIR compares in its sector
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ATEA PHARMACEUTICALS INC looks technically
ATEA PHARMACEUTICALS INC (AVIR) is trading 6.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 194 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 20.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +6.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.24 | $5.24 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.84 | $4.84 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 5.655. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 194 trading days ago — a "golden cross", a bullish long-term signal | 194 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($4.91 to $5.66) — its "stochastic" reading is 33 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 32.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.45 | $6.45 |
|---|---|---|
| From the 52-week high | it is 20.1% below its 52-week high (its highest price of the past year) | -20.1% |
| Above the 52-week low | it is 83.8% above its 52-week low (its lowest price of the past year) | +83.8% |
| Below the 52-week high | it is 20.1% below its highest point of the past year | 20.1% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 24 trading days ago | 24 sessions |
| All-time high | its highest closing price on record is $94.17 (set on 2021-02-11) | $94.17 |
| Given back of the 52-week move | over the past year its closes ranged ($2.90 to $6.15), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.04 to $4.14. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.6% |
| From the all-time high | it is 94.5% below its all-time high | -94.5% |
| Nearest price level | it is trading 2.4% above a support level at $5.03 — a price it turned at twice since 2026-03-30, most recently on 2026-07-02. Since 2024-10-08 it has 12 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.4% |
| All-time low | its lowest closing price on record is $2.46 (set on 2025-05-15) | $2.46 |
| Above the all-time low | it is 110.0% above its all-time low | +110.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2261 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2261 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.95 and $5.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.95 – $5.22 – $5.50 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (6.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.26× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
4
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 32 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 32 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.3 percentage points (the stock lost 9.2% while the market gained 1.0%) | -10.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.3 percentage points (the stock gained 7.2% while the market gained 3.8%) | +3.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 29.6 percentage points (the stock lost 12.2% while the market gained 17.5%) | -29.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 51.3 percentage points (the stock gained 66.3% while the market gained 15.0%) | +51.3% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.9% of the share price. | +1.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.89 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +5.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.30 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | -2.7% |
Price levels it has turned at before
AVIR last closed at $5.16 on 2026-10-08. Since 2024-10-08 it has turned at 12 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.03 | Support | 2.4% below the last close | turned there twice · 2026-03-30 to 2026-07-02 |
| $5.65 | Resistance | 9.6% above the last close | turned there twice · 2026-08-21 to 2026-09-22 |
| $4.60 | Support | 10.8% below the last close | turned there twice · 2026-06-12 to 2026-07-14 |
| $5.87 | Resistance | 13.8% above the last close | turned there twice · 2026-05-05 to 2026-09-04 |
| $4.03 | Support | 21.8% below the last close | turned there twice · 2025-07-28 to 2026-05-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $5.66.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · lagging the market · Printed a bullish engulfing pair | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$9.42 range $7.00 – $11.25; median $10.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVIR
- Consensus EPS estimate-$0.505 next reporting period, as of 2026-10-06
- Estimate change, 30 days$0.00 from -$0.505, on 2026-09-01, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the success of the bemnifosbuvir/ruzasvir combination for future revenue.","Significant clinical development and regulatory risks, including potential failure to secure FDA approval for NDA submissions.","Operating in a highly competitive market against well-established incumbents with significant resources."]
What changed in the latest 10-Q
AI-assisted comparison of AVIR's 10-Q filed 2026-08-12 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds the fixed-dose combination ("FDC") descriptor to the BEM/RZR regimen in the HCV program objective.
- Newer filing adds a paragraph on chronic HCV infection as a public health crisis, citing WHO data (cited July 28, 2026) of approximately 50 million people worldwide living with HCV, including up to 4 million in the US.
- Newer filing adds that roughly 80% of people living with HCV take multiple concomitant medications for common comorbidities such as heartburn, heart arrhythmia, high blood pressure and GERD.
- Newer filing adds that C-BEYOND topline results were announced in July 2026 with BEM/RZR demonstrating statistical non-inferiority compared to SOF/VEL in the mITT population.
- Newer filing adds detailed C-BEYOND mITT results: n=905, BEM/RZR 93.9% SVR vs. SOF/VEL 94.8% at Week 24; non-cirrhotic n=721, BEM/RZR 93.5% SVR (8 weeks) vs. SOF/VEL 94.6% (12 weeks); cirrhotic n=184, BEM/RZR 95.4% SVR vs. SOF/VEL 95.4%.
- Newer filing adds that C-BEYOND rates of virologic failure were low and comparable between arms, and statistical non-inferiority was also met in secondary endpoints including per-protocol analysis.
- Newer filing adds that BEM/RZR was generally safe and well tolerated in C-BEYOND with no drug-related serious adverse events or drug-related early treatment discontinuations.
- Newer filing adds that C-FORWARD is being conducted at approximately 120 sites in 17 countries outside North America.
- Newer filing adds that C-FORWARD enrollment of more than 880 HCV patients was completed in June 2026.
- Newer filing adds that C-FORWARD topline results are anticipated early in the first quarter of 2027.
- Newer filing adds NDA submission target of second quarter of 2027 pending successful C-FORWARD results.
- Removed:
- Older filing states C-BEYOND is fully enrolled with over 880 patients and topline results expected mid-2026.
- Older filing states C-FORWARD enrollment of approximately 880 patients was anticipated to complete in mid-2026 with topline results at year-end 2026.
- Older filing states NDA submission target of March 2027 pending successful Phase 3 results.
- Older filing states the HCV figure of up to four million persons in the US is reported by the US Center for Disease Control and Prevention.
- Older filing includes the sentence that US accounts for approximately 50% of the $2.5 billion global branded HCV therapeutic sales.
- Older filing includes the statement that CMC strategy will provide FDC tablets for the completion of the Phase 3 program.
- Older filing includes the entire HEV section (HEV - Our Goal and Our Program) with AT-587 details, anticipated Phase 1 initiation mid-2026, and the portfolio statement.
- Older filing includes the section 'Discovery efforts for other RNA virus infections' describing the compound library and evaluation of select compounds.
- Older filing includes the section 'Financial Resources' with cash, cash equivalents and marketable securities of $256.0 million at March 31, 2026 and statements about no approved products or product revenue.
- Reworded:
- Newer filing changes reference from 'the regimen of bemnifosbuvir and ruzasvir' to 'the fixed-dose combination ("FDC") regimen of BEM/RZR' in the HCV development program objective.
- Newer filing changes description of clinical/nonclinical results from 'studies conducted to date, including a global Phase 2 clinical trial which enrolled 275 HCV infected patients' to 'studies we conducted prior to our Phase 3 program' and changes 'high potency' to 'high antiviral potency'.
- Newer filing changes the comparator description from 'the regimen of sofosbuvir and velpatasvir' to 'the fixed-dose combination regimen of sofosbuvir and velpatasvir ("SOF/VEL" marketed in the US under the brand Epclusa®)'.
- Newer filing changes CMC wording from 'provide fixed dose combination ("FDC") tablets for the completion of the Phase 3 program, to fulfill NDA requirements and to prepare us for potential launch with sufficient commercial supply for projected initial sales' to 'manufacture BEM/RZR FDC tablets to fulfill NDA requirements and prepare us for potential launch'.
- Newer filing adds 'if successfully developed and approved' to the sentence on a novel, shorter duration, easily prescribable treatment benefiting today's HCV patient population.
- Newer filing changes the US HCV population description from 'as many as four million persons in the US' (attributed to CDC) to 'up to 4 million people in the US' (attributed to WHO).
- Notes:
- The newer filing text is truncated mid-sentence in the final paragraph on branded HCV therapeutics ('with the US accounting for appro'), so later portions of the newer MD&A (including any HEV section, discovery efforts, or financial resources sections that may exist) could not be compared.
- The older filing text is truncated mid-sentence in the Financial Resources section ('Our ability to generate product revenue will depend on the successful develo'), so later portions of the older MD&A could not be compared.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-041 buy ($25446) · 0 sells — 1 buying insider
Most recent open-market transaction: 2026-05-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVIR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AVIR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 23,822,188
- Reported value $110,773,177
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AVIR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AVIR had 7,630,075 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AVIR had 9.51% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 27.3 days to cover at the same settlement.
- Reported short interest (shares) 7,630,075
- Short interest (% of shares outstanding) 9.51%
- Prior settlement (shares) 7,663,720
- Reported change -0.44%
- Days to cover (reported) 27.3
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVIR vs…
Frequently asked questions
What does ATEA PHARMACEUTICALS INC (AVIR) do?
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing orally administered, direct-acting antiviral therapies for serious viral diseases. Its pipeline centers on a proprietary nucleos(t)ide platform used to create candidates such as the bemnifosbuvir and ruzasvir combination for hepatitis C and AT-587 for chronic hepatitis E. The company is currently conducting late-stage clinical trials to address significant unmet medical needs in hepatology.
What sector is ATEA PHARMACEUTICALS INC (AVIR) in?
ATEA PHARMACEUTICALS INC (AVIR) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ATEA PHARMACEUTICALS INC's (AVIR) competitors?
Notable peers of ATEA PHARMACEUTICALS INC (AVIR) include Gilead Sciences and AbbVie. This peer set is informational only — not financial advice.
Is ATEA PHARMACEUTICALS INC (AVIR) overbought or oversold right now?
ATEA PHARMACEUTICALS INC (AVIR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVIR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.